The jealous rants won't make the stock go away. Keep on hoping and praying that nothing works and telling your lies as they at IONS accumulates more cash every year, more drugs in the pipeline every year, and more big pharma partners that believe in what they see. You chums are forever ruining your futures by wasting your time, getting your hopes up that they fail, and betting on a true failure in vicl. But you know, I really don't care what happens with vicl......If I did I'd be on THAT board. t
You are telling a lie and calling others a liar. Tudy you really look bad. t
Rexahn Pharmaceuticals completes stage 1 and begins enrollment in stage 2 of Archexin phase iia clinical trial in Metastatic Renal Cell Carcinoma (0.36)
The chums are going to find out shortly Country. We can only feel bad for them, and happy for ourselves. t
Not a lot of new big news but the company continues to do what they said they were going to do and that is advance products through the pipeline. With a total of five trials coming up from three drugs there certainly are quite a few shots on goal. The basis for Phase II data isn't really being based on efficacy, but if there is continued survival improvement and tumor reduction in size that will count to wall street as some fair amount of increase in chances for success. What would be nice would be to see in the literature from more oncologists recognition of this "gemcitabine" effect. Don't let wall street shake your shares lose. t
He is a professional hack. So arrogant that he wouldn't give you the time of day unless you paid him. Says he is unfairly chastised and yet he would regularly say you low lifes come out from underneath your rocks to say such and such. Hold shares tight, don't invest more than you can afford to lose or sleep at night, follow it closely AND blow Mr. Putin OFF. t
Mr. Putin posts eight out of twenty posts......for free as arrogant as he is. He brags about himself and where he goes, and yet for us low life's he is willing to give us the same old advice over and over again. A paid hack who is all for himself. My advice is if you do respond to him, change the heading in regards to your response so he doesn't get paid..... Probably based on this variable. Let him short the stock on his own, let's not help him. And don't help pay for his tan!! t
Woof woof, you are one stupid dog if you bought more vicl. Lassie, why don't you tell everyone here, even though you are on the wrong board, what vicl has coming on downstream that even makes ant sense to do that at all assuming you are all ready heavily into this company based on your previous verbiage as too how much of it you were holding?!? t
You are talking right eggs even if you are doing it facially. This going to happen and they numbers with the patients in need are there. vick has nothing going for it over the short to intermediates tern. A lot of fluff, but nothing real world coming forward from then. t
Never hide, you only wish that I would. Your being on the wrong board and devoid of any up to date knowledges makes you chums even less formidable. You chums will chech out, become more jealous, or try and grow with the IONS people. t
Dark made a huge mistake with that recommendation.......And it was on the wrong board.m goes to show you
Many dummies there really are out there. t
Your name sounds more female than mine....I wonder if your computer has protection for threatening people or taunting them and being able to back it up in real life. Or if you would so easily taunt a person if it were real life! Of course your owning vicl.and coming over to another board kind of explains your confidence in the med. t
Woof woof away, it is a dog stock that sells for over 80% from which it did over 30 years age.
Rudy, you are the real girl chum, I can tell by your name,! You don't really understand advancements that have occurred. One question Tudy girl, do you live I a home built in the 1940's and the real estate agent told you that the house was "stats of the ART?'.
I noted that I was not going to read propaganda from Mr. Putin. I accidentally did when his little sound bite about attention and a superiority type play came out of his mouth. People let's look at this situation. We have a little biotech with maybe a huge play in CA by taking a unique approach and going after targets that are cancer cells that have unique biomarkers to only cancer cells. In the past I've not ever seen that distinct approach. Other companies that didn't have this much going for it have made it big. On top of that you have this so-called semi-dead company according to Mr. P that isn't going anywhere because it never went anywhere in the past. This little biotech company has held up extremely well through these extremely tough three weeks of all stocks, but biotechs in particular. We have potentially good products, technically a strong pricing situation over maybe the toughest time since 2008, and what I feel is good progress in the clinical studies. Mr. P asks if I want attention? I love biotech, I have a network of friends who help me and we work together. I try not to talk about the same thing all of the time......esp. not the obvious. Thus I feel we have a good chance of having something special with this company. If someone really isn't in it for the long term, even if the company hits the 3 handle like many analyst think it can that would be a tremendous investment for those individuals. My question goes back to Mr. P who posts clearly 40% of the posts here......do you want attention? Which really is a minor thing, or are you worse and you have an agenda and you are paid for it? t
Invacare (INCY) is down ~25% today after announcing earnings and disclosing that is was discontinuing its JANUS studies. INCY beat eps by $0.20/share and beat on revs by ~$18 mln. In a separate press release, co announced its decision to discontinue the Phase 3 study (JANUS 1) of ruxolitinib or placebo in combination with capecitabine for the second-line treatment of patients with advanced or metastatic pancreatic cancer. The decision to stop the study was made after a planned interim analysis of JANUS 1 demonstrated that ruxolitinib plus capecitabine did not show a sufficient level of efficacy to warrant continuation. Incyte's dose finding study of INCB39110 (a selective JAK1 inhibitor) as first-line treatment for metastatic pancreatic cancer, will also be discontinued.
Puma Biotech's ExteNET Phase III clinical trial met primary endpoints (36.55)
Results from the ExteNET Phase III clinical trial of neratinib in patients with early stage HER2 positive breast cancer were published in the journal The Lancet Oncology.The study demonstrated that the trial hit its primary endpoint and that treatment with neratinib resulted in a 33% reduction of risk of invasive disease recurrence or death versus placebo (hazard ratio = 0.67, p = 0.009).
Got remember however that almost 40% of the patient's experienced significant diarrhea. t
I don't see a way out of their trap. Mr. Beer spent all of their money on a drug that probably won't pay off. They say that they need to get a second generation juxapid. Where is the money going to come from to do this? They will want to promote their new drug....won't be as easy with less drug reps. And frankly I don't see that drug ever paying off. Their diarrhea problem with juxtapid was supposed to be solved according to Mr. Beer by expanding their COMPASS Program. The reason why they went from only 15% diarrhea in their flimsy study to 41% diarrhea in the real world is because it is the real world. With less nurses in their COMPASS Program to watch these people like a hawk I think that their diarrhea problem will worsen. You have a new CEO and a new CMO that is going to take time an money to get them up to speed. You have PCSK9 inhibitors that will take some business away. And this company is one inch away from coming under scrutiny from politicians. To just look at it superficially, you have an over 20 year drug that costs $400K per patient per year, that hasn't proven anything in regards to reducing CV disease in this climate. t
Dark, asking you to rethink your message about vicl. You and the chums are heading for BK of your company. Nothing coming down the road for them in the foreseeable future, no way to get the share price above a buck without having a 5 for 1 reverse split, probable delisting, the huge exodus out of biotech in general in weak biotechs specifically. This really is a losing situation. Hoping you really aren't invested in this glob from Mars stock. t